These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32965010)

  • 1. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
    Quagliariello V; Bonelli A; Caronna A; Lombari MC; Conforti G; Libutti M; Iaffaioli RV; Berretta M; Botti G; Maurea N
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):9169-9171. PubMed ID: 32965010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the NLRP3 Inflammasome in Severe COVID-19.
    Freeman TL; Swartz TH
    Front Immunol; 2020; 11():1518. PubMed ID: 32655582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury.
    Irrera N; Russo M; Pallio G; Bitto A; Mannino F; Minutoli L; Altavilla D; Squadrito F
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe COVID-19: NLRP3 Inflammasome Dysregulated.
    van den Berg DF; Te Velde AA
    Front Immunol; 2020; 11():1580. PubMed ID: 32670297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.
    Agarwal S; Pethani JP; Shah HA; Vyas V; Sasane S; Bhavsar H; Bandyopadhyay D; Giri P; Viswanathan K; Jain MR; Sharma R
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127571. PubMed ID: 32980515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research.
    Lipman M; Chambers RC; Singer M; Brown JS
    Thorax; 2020 Aug; 75(8):614-616. PubMed ID: 32461230
    [No Abstract]   [Full Text] [Related]  

  • 7. Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19.
    Khider L; Soudet S; Laneelle D; Boge G; Bura-Rivière A; Constans J; Dadon M; Desmurs-Clavel H; Diard A; Elias A; Emmerich J; Galanaud JP; Giordana P; Gracia S; Hamade A; Jurus C; Le Hello C; Long A; Michon-Pasturel U; Mirault T; Miserey G; Perez-Martin A; Pernod G; Quere I; Sprynger M; Stephan D; Wahl D; Zuily S; Mahe G; Sevestre MA;
    J Med Vasc; 2020 Jul; 45(4):210-213. PubMed ID: 32571561
    [No Abstract]   [Full Text] [Related]  

  • 8. Inflammasomes during SARS-CoV-2 infection and development of their corresponding inhibitors.
    Diarimalala RO; Wei Y; Hu D; Hu K
    Front Cell Infect Microbiol; 2023; 13():1218039. PubMed ID: 37360532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19.
    Kroemer A; Khan K; Plassmeyer M; Alpan O; Haseeb MA; Gupta R; Fishbein TM
    J Hepatol; 2020 Nov; 73(5):1258-1262. PubMed ID: 32645361
    [No Abstract]   [Full Text] [Related]  

  • 10. Venous thromboembolism in critically ill patients affected by ARDS related to COVID-19 in Northern-West Italy.
    Longhitano Y; Racca F; Zanza C; Piccioni A; Audo A; Muncinelli M; Santi R; Kozel D; Geraci C; Taverna M; Bonato V; Cassini F; Franceschi F
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):9154-9160. PubMed ID: 32965007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
    Yaqinuddin A; Kashir J
    Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting a SARS-CoV-2/COVID Molecular Testing Method for Your Laboratory.
    Greene DN
    J Appl Lab Med; 2020 Jul; 5(4):837-840. PubMed ID: 32761155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Special Issue on Diagnostic Testing for Severe Acute Respiratory Syndrome Coronavirus 2 and Lessons from This Pandemic.
    McAdam AJ
    J Clin Microbiol; 2020 Jul; 58(8):. PubMed ID: 32703896
    [No Abstract]   [Full Text] [Related]  

  • 14. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.
    Zhao N; Di B; Xu LL
    Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. My Experience with SARS-CoV-2, with a Focus on Testing.
    Cotter PA
    J Clin Microbiol; 2020 Jul; 58(8):. PubMed ID: 32703893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammasome formation in the lungs of patients with fatal COVID-19.
    Toldo S; Bussani R; Nuzzi V; Bonaventura A; Mauro AG; Cannatà A; Pillappa R; Sinagra G; Nana-Sinkam P; Sime P; Abbate A
    Inflamm Res; 2021 Jan; 70(1):7-10. PubMed ID: 33079210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of SARS-CoV-2 in Hemodialysis Effluent of Patient with COVID-19 Pneumonia, Japan.
    Okuhama A; Ishikane M; Katagiri D; Kanda K; Nakamoto T; Kinoshita N; Nunose N; Fukaya T; Kondo I; Katano H; Suzuki T; Ohmagari N; Hinoshita F
    Emerg Infect Dis; 2020 Nov; 26(11):2758-2761. PubMed ID: 32730734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 infection presenting as a febrile rash.
    Amatore F; Macagno N; Mailhe M; Demarez B; Gaudy-Marqueste C; Grob JJ; Raoult D; Brouqui P; Richard MA
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e304-e306. PubMed ID: 32330336
    [No Abstract]   [Full Text] [Related]  

  • 19. [Not Available].
    Balavoine JF
    Rev Med Suisse; 2020 Sep; 16(706):1726. PubMed ID: 32936565
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.
    Shah A
    Front Immunol; 2020; 11():1021. PubMed ID: 32574259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.